Compare Stocks: CRMD, SUPN, HRMY, and OCUL

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CRMD CorMedix	$7.72 -0.9%	$7.96	$6.13 ▼ $13.02	$601.73M	1.5	862,884 shs	1.81 million shs
HRMY Harmony Biosciences	$42.02 -1.7%	$38.57	$25.52 ▼ $43.49	$2.45B	0.93	836,531 shs	3.82 million shs
OCUL Ocular Therapeutix	$9.99 -1.5%	$9.88	$6.23 ▼ $16.44	$2.19B	0.97	2.01 million shs	4.10 million shs
SUPN Supernus Pharmaceuticals	$42.00 -2.1%	$45.51	$40.51 ▼ $59.68	$2.45B	0.56	545,266 shs	1.18 million shs

The 7 Hottest IPO Stories of 2026

MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CRMD CorMedix	0.00%	-1.28%	-6.20%	-10.96%	-30.58%
HRMY Harmony Biosciences	0.00%	+1.20%	+10.38%	+26.26%	+31.07%
OCUL Ocular Therapeutix	0.00%	-4.77%	-9.92%	+5.94%	-17.85%
SUPN Supernus Pharmaceuticals	0.00%	+0.86%	-11.49%	-5.36%	-6.25%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CRMD CorMedix	$7.72 -0.9%	$7.96	$6.13 ▼ $13.02	$601.73M	1.5	862,884 shs	1.81 million shs
HRMY Harmony Biosciences	$42.02 -1.7%	$38.57	$25.52 ▼ $43.49	$2.45B	0.93	836,531 shs	3.82 million shs
OCUL Ocular Therapeutix	$9.99 -1.5%	$9.88	$6.23 ▼ $16.44	$2.19B	0.97	2.01 million shs	4.10 million shs
SUPN Supernus Pharmaceuticals	$42.00 -2.1%	$45.51	$40.51 ▼ $59.68	$2.45B	0.56	545,266 shs	1.18 million shs

The 7 Hottest IPO Stories of 2026

MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CRMD CorMedix	0.00%	-1.28%	-6.20%	-10.96%	-30.58%
HRMY Harmony Biosciences	0.00%	+1.20%	+10.38%	+26.26%	+31.07%
OCUL Ocular Therapeutix	0.00%	-4.77%	-9.92%	+5.94%	-17.85%
SUPN Supernus Pharmaceuticals	0.00%	+0.86%	-11.49%	-5.36%	-6.25%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CRMD CorMedix	2.75	Moderate Buy	$15.00	94.30% Upside
HRMY Harmony Biosciences	2.36	Hold	$47.11	12.12% Upside
OCUL Ocular Therapeutix	2.77	Moderate Buy	$25.75	157.76% Upside
SUPN Supernus Pharmaceuticals	2.43	Hold	$62.83	49.60% Upside

Current Analyst Ratings Breakdown

Latest CRMD, SUPN, HRMY, and OCUL Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
9/16/2026	OCUL Ocular Therapeutix	Chardan Capital Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$23.00
9/16/2026	OCUL Ocular Therapeutix	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$25.00
9/4/2026	SUPN Supernus Pharmaceuticals	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
8/26/2026	HRMY Harmony Biosciences	Wolfe Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Outperform	$60.00
8/17/2026	HRMY Harmony Biosciences	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Hold (C) ➝ Hold (C+)
8/14/2026	CRMD CorMedix	Royal Bank Of Canada Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Outperform	$13.00 ➝ $14.00
8/12/2026	OCUL Ocular Therapeutix	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Strong Sell ➝ Hold
8/11/2026	CRMD CorMedix	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Hold (C)
8/11/2026	HRMY Harmony Biosciences	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
8/6/2026	SUPN Supernus Pharmaceuticals	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Hold ➝ Strong-Buy
8/5/2026	HRMY Harmony Biosciences	Deutsche Bank Aktiengesellschaft Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Hold	$39.00

(Data available from 9/20/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CRMD CorMedix	$311.71M	1.93	$2.05 per share	3.77	$5.14 per share	1.50
HRMY Harmony Biosciences	$868.45M	2.82	$3.18 per share	13.21	$15.11 per share	2.78
OCUL Ocular Therapeutix	$52.06M	42.15	N/A	N/A	$3.07 per share	3.25
SUPN Supernus Pharmaceuticals	$718.95M	3.40	$3.78 per share	11.12	$18.52 per share	2.27

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CRMD CorMedix	$163.05M	$2.14	3.61	55.14	N/A	40.49%	40.52%	20.61%	11/11/2026 (Estimated)
HRMY Harmony Biosciences	$158.69M	$3.08	13.64	10.56	0.39	18.88%	20.06%	14.15%	11/3/2026 (Estimated)
OCUL Ocular Therapeutix	-$265.94M	-$1.42	N/A	N/A	N/A	-579.10%	-59.89%	-45.99%	11/3/2026 (Estimated)
SUPN Supernus Pharmaceuticals	-$38.55M	-$1.92	N/A	10.88	0.77	-13.23%	11.13%	8.10%	11/3/2026 (Estimated)

Latest CRMD, SUPN, HRMY, and OCUL Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/13/2026	Q2 2026	CRMD CorMedix	$0.2380	$0.29	+$0.0520	$0.29	$96.04 million	$101.93 million
8/4/2026	Q2 2026	HRMY Harmony Biosciences	$0.9560	$1.28	+$0.3240	$1.28	$250.77 million	$261.28 million
8/3/2026	Q2 2026	OCUL Ocular Therapeutix	-$0.3955	-$0.35	+$0.0455	-$0.35	$13.20 million	$13.48 million
8/3/2026	Q2 2026 & Merger	SUPN Supernus Pharmaceuticals	$0.4225	-$1.01	-$1.4325	-$1.01	$205.31 million	$219.06 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
CRMD CorMedix	N/A	N/A	N/A	N/A	N/A
HRMY Harmony Biosciences	N/A	N/A	N/A	N/A	N/A
OCUL Ocular Therapeutix	N/A	N/A	N/A	N/A	N/A
SUPN Supernus Pharmaceuticals	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CRMD CorMedix	0.31	2.56	2.36
HRMY Harmony Biosciences	0.13	3.48	3.45
OCUL Ocular Therapeutix	0.14	13.10	13.03
SUPN Supernus Pharmaceuticals	N/A	2.08	1.84

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CRMD CorMedix	34.18%
HRMY Harmony Biosciences	86.23%
OCUL Ocular Therapeutix	59.21%
SUPN Supernus Pharmaceuticals	N/A

Insider Ownership

Company	Insider Ownership
CRMD CorMedix	3.50%
HRMY Harmony Biosciences	11.00%
OCUL Ocular Therapeutix	3.10%
SUPN Supernus Pharmaceuticals	8.50%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CRMD CorMedix	191	77.94 million	75.22 million	Optionable
HRMY Harmony Biosciences	293	58.24 million	51.83 million	Optionable
OCUL Ocular Therapeutix	325	219.62 million	212.81 million	Optionable
SUPN Supernus Pharmaceuticals	778	58.22 million	53.28 million	Optionable

CRMD, SUPN, HRMY, and OCUL Headlines

Recent News About These Companies

Branded Pharmaceuticals Stocks Q2 Results: Benchmarking Supernus Pharmaceuticals (NASDAQ:SUPN)

September 20 at 7:49 AM | finance.yahoo.com

Why Did Supernus Pharmaceuticals (SUPN) Move Today?

September 19 at 9:37 AM | finance.yahoo.com

How Supernus’ Q2 Beat and Raised Guidance Could Reshape Supernus Pharmaceuticals (SUPN) Investors’ Outlook

September 19 at 9:37 AM | finance.yahoo.com

Engineers Gate Manager LP Makes New $1.12 Million Investment in Supernus Pharmaceuticals, Inc. $SUPN

September 19 at 3:13 AM | marketbeat.com

Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) Receives Average Recommendation of "Hold" from Brokerages

September 18 at 6:13 AM | marketbeat.com

Indivior Pharmaceuticals Declares $8.13 Special Cash Dividend Contingent on Supernus Merger Closing

September 17 at 7:31 AM | quiverquant.comQ

Supernus Pharmaceuticals (NASDAQ:SUPN) Hits New 12-Month Low - What's Next?

September 15, 2026 | marketbeat.com

Supernus Pharmaceuticals (NASDAQ:SUPN) Hits New 1-Year Low - Time to Sell?

September 8, 2026 | marketbeat.com

Jupiter Topco LLC Buys Shares of 23,254 Supernus Pharmaceuticals, Inc. $SUPN

September 6, 2026 | marketbeat.com

The Manufacturers Life Insurance Company Invests $1.30 Million in Supernus Pharmaceuticals, Inc. $SUPN

September 5, 2026 | marketbeat.com

Legal & General Group Plc Purchases New Position in Supernus Pharmaceuticals, Inc. $SUPN

September 3, 2026 | marketbeat.com

Supernus Pharmaceuticals to Participate in September Investor Conferences

September 2, 2026 | globenewswire.com

Bank of New York Mellon Corp Makes New $17.55 Million Investment in Supernus Pharmaceuticals, Inc. $SUPN

September 1, 2026 | marketbeat.com

Chloe Kim Teams Up with Qelbree®, the #1 Prescribed Branded Non-Stimulant ADHD Treatment*, to Help Empower People Navigating ADHD

August 31, 2026 | globenewswire.com

156,422 Shares in Supernus Pharmaceuticals, Inc. $SUPN Bought by Man Group plc

August 30, 2026 | marketbeat.com

SUPN Stock Alert: Halper Sadeh LLC is Investigating Whether Supernus Pharmaceuticals, Inc. is Obtaining a Fair Price for its Shareholders

August 29, 2026 | businesswire.com

Freestone Grove Partners LP Invests $14.72 Million in Supernus Pharmaceuticals, Inc. $SUPN

August 28, 2026 | marketbeat.com

91,070 Shares in Supernus Pharmaceuticals, Inc. $SUPN Acquired by Algert Global LLC

August 28, 2026 | marketbeat.com

25,858 Shares in Supernus Pharmaceuticals, Inc. $SUPN Acquired by PDT Partners LLC

August 27, 2026 | marketbeat.com

Deutsche Bank AG Takes $2.96 Million Position in Supernus Pharmaceuticals, Inc. $SUPN

August 27, 2026 | marketbeat.com

Elmind Capital LP Invests $3.26 Billion in Supernus Pharmaceuticals, Inc. $SUPN

August 26, 2026 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

CRMD, SUPN, HRMY, and OCUL Company Descriptions

CorMedix NASDAQ:CRMD

$7.72 -0.07 (-0.90%)

Closing price 09/18/2026 04:00 PM Eastern

Extended Trading

$7.75 +0.03 (+0.40%)

As of 09/18/2026 07:44 PM Eastern

CorMedix Inc., a biopharmaceutical company, focuses on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases in the United States. Its lead product candidate is DefenCath, an antimicrobial catheter lock solution to reduce the incidence of catheter-related bloodstream infections in adult patients with kidney failure. The company was formerly known as Picton Holding Company, Inc. and changed its name to CorMedix, Inc. in January 2007. CorMedix Inc. was incorporated in 2006 and is based in Berkeley Heights, New Jersey.

Harmony Biosciences NASDAQ:HRMY

$42.02 -0.72 (-1.68%)

Closing price 09/18/2026 04:00 PM Eastern

Extended Trading

$41.83 -0.19 (-0.45%)

As of 09/18/2026 07:30 PM Eastern

Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare and other neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy. It also offers HBS-102, a melanin-concentrating hormone receptor 1 for MCH neurons. The company was formerly known as Harmony Biosciences II, Inc. and changed its name to Harmony Biosciences Holdings, Inc. in February 2020. Harmony Biosciences Holdings, Inc. was incorporated in 2017 and is headquartered in Plymouth Meeting, Pennsylvania.

Ocular Therapeutix NASDAQ:OCUL

$9.99 -0.15 (-1.48%)

Closing price 09/18/2026 04:00 PM Eastern

Extended Trading

$10.10 +0.11 (+1.06%)

As of 09/18/2026 07:30 PM Eastern

Ocular Therapeutix, Inc., a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel-based formulation technology in the United States. The company markets DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis. It is developing AXPAXLI, an axitinib intravitreal implant that is in phase 3 trials for the treatment of wet age-related macular degeneration and other retinal diseases; PAXTRAVA, a travoprost intracameral implant, which is in phase 2 clinical trials for the treatment of open-angle glaucoma or ocular hypertension; OTX-CSI, a cyclosporine intracanalicular insert that has completed phase 2 clinical trials for the treatment of dry eye disease; and OTX-DED, a dexamethasone intracanalicular insert, which is in phase 2 clinical trials for the short-term treatment of the signs and symptoms of dry eye disease. In addition, the company offers modulator for intermediate and late dry age-related macular degeneration; and gene delivery for inherited retinal degenerations and protein biofactory indications. The company has a strategic collaboration with Regeneron Pharmaceuticals, Inc. (Regeneron) for the development and commercialization of products using the company's sustained-release hydrogel in combination with Regeneron's large molecule VEGF-targeting compounds for the treatment of retinal diseases; and AffaMed Therapeutics Limited for the development and commercialization of DEXTENZA and OTX-TIC. Ocular Therapeutix, Inc. was incorporated in 2006 and is headquartered in Bedford, Massachusetts.

Supernus Pharmaceuticals NASDAQ:SUPN

$42.00 -0.92 (-2.14%)

As of 09/18/2026 04:00 PM Eastern

Supernus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company's commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age. It also offers comprise Qelbree, a novel non-stimulant indicated for the treatment of attention-deficit hyperactivity disorder (ADHD) in adults and pediatric patients 6 years and older; APOKYN for the acute intermittent treatment of hypomobility or off episodes in patients with advanced Parkinson's Disease (PD); XADAGO for treating levodopa/carbidopa in patients with PD experiencing off episodes; MYOBLOC, a Type B toxin product indicated for the treatment of cervical dystonia and sialorrhea in adults; GOCOVRI for the treatment of dyskinesia in patients with PD; and Osmolex ER for the treatment of Parkinson's disease and drug-induced extrapyramidal reaction in adult patients. In addition, the company's product candidates include SPN-830, a late-stage drug/device combination product candidate for the treatment of off episodes in PD patients; SPN-817, a novel first-in-class selective acetylcholinesterase inhibitor, which is in Phase II clinical trials for the treatment of epilepsy; SPN-820, a product candidate in Phase II clinical trials for treating resistant depression; SPN-443, a preclinical product for the treatment of ADHD/CNS; and SPN-446 for narcolepsy and SPN-448 for the treatment of CNS which is in discovery stage. It markets and sells its products through pharmaceutical wholesalers, specialty pharmacies, and distributors. Supernus Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Rockville, Maryland.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest CRMD, SUPN, HRMY, and OCUL Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest CRMD, SUPN, HRMY, and OCUL Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

CRMD, SUPN, HRMY, and OCUL Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

CRMD, SUPN, HRMY, and OCUL Company Descriptions

CorMedix NASDAQ:CRMD

Harmony Biosciences NASDAQ:HRMY

Ocular Therapeutix NASDAQ:OCUL

Supernus Pharmaceuticals NASDAQ:SUPN

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest CRMD, SUPN, HRMY, and OCUL Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest CRMD, SUPN, HRMY, and OCUL Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

CRMD, SUPN, HRMY, and OCUL Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

CRMD, SUPN, HRMY, and OCUL Company Descriptions

CorMedix NASDAQ:CRMD

Harmony Biosciences NASDAQ:HRMY

Ocular Therapeutix NASDAQ:OCUL

Supernus Pharmaceuticals NASDAQ:SUPN

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools